a nonsignificant trendP = 0.17
In fact, the first trial, the CHAMPION PLATFORM trial, 9 comparing cangrelor vs clopidogrel in more than 5,000 patients undergoing percutaneous coronary intervention, observed a nonsignificant trend of benefit with cangrelor (HR: 0.87; P = 0.17).